TrialESMO open2022

Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11).

Y Sunakawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.